Pulsar

Pulsar Therapeutics is a pre-clinical stage biotechnology company dedicated to expanding the therapeutic potential of RNA-based medicines. The company focuses on overcoming the historical challenge of delivering nucleic acids to tissues beyond the liver, such as the central nervous system and skeletal muscle. Utilizing its proprietary Pulsar platform, the company develops ligand-conjugated oligonucleotides designed for high precision and potency in extrahepatic organs. Pulsar was incubated by Longwood Fund and is led by a management team with extensive experience in the development and commercialization of orphan drugs and RNA therapies. The company's mission is to address significant unmet needs in rare genetic disorders and other complex diseases currently underserved by standard delivery technologies.